// App-Quantinova.ai

11518.0 : A phase II single-arm study of nivolumab and ipilimumab (Nivo/Ipi) in previously treated classical Kaposi sarcoma (CKS).

Researchers

Presenter

  • Alona Zer

Principal Investigators

  • Lilach Joseph

  • Dana Avram

  • Oded Jacobi

  • Eyal Fenig

  • Noga Kurman

  • Idit Peretz

  • Sivan Shamai

  • Ofer Merimsky

  • Eitan Ben-Ami

  • Roni Shapira

  • Anna Ewa Schwarzbach

  • Hanna Bernstine

  • Rony Weitzen

  • Olga Vornicova

  • Gil Bar-Sela

  • Salomon M. Stemmer

  • Michal Lotem

Medical Centers

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Thoracic Cancer Unit, Davidoff Cancer Institute, Rabin Medical Center, affiliated to the Sackler Faculty of Medicine, Petach Tiqwa, Israel

  • Rabin Medical Center, Petach Tikvah, Israel

  • Davidoff Cancer Center, Rabin Medical Center-Beilinson Hospital, Petah Tikva, Israel

  • Davidoff Center, Rabin Medical Center, Petach-Tikva, Israel

  • Tel Aviv Sourasky Medical Centre, Tel Aviv, Israel

  • Tel Aviv Medical Center affiliated with Sackler School of Medicine, Tel Aviv, Israel

  • Chaim Sheba Medical Center, Tel Hashomer, Israel

  • Asuragen, Inc., Austin, TX

  • Chaim Sheba Medical Center, Tel Hashomer, Israel

  • Ha'emek Medical Center, Afula, Israel

  • Ha'emek Medical Center, Afula, Israel

  • Davidoff Cancer Center, Rabin Medical Center-Beilinson Hospital, Petah Tikva, Israel

  • Hadassah Medical Center, Jerusalem, Israel

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Cluster of Differentiation 206

  • Programmed cell death protein 1

  • Programmed death-ligand 1

  • Cytotoxic T-lymphocyte-associated protein 4

  • Microsatellite instability

  • Tumor mutational burden

Drug/Treatment

  • Ipilimumab

  • Nivolumab

Outcome

  • N/A

Study Design

  • Single Arm

Phase

  • NA

Study Id's

  • NCT03219671

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved